Antibodies generated in vitro and in vivo elucidate design of a thermostable ADDomer COVID-19 nasal nanoparticle vaccine
D. Buzas, H. A. Bunzel, O. Staufer, E. Milodowski, G. Edmonds, J. Bufton, B. Vidana Matteo, S. Yadav, K. Gupta, C. Fletcher, M. Kavanagh Williamson, A. Harrison, U. Borucu, J. Capin, O. Francis, , I. Berger
This study develops a thermostable ADDomer-based nanoparticle vaccine that neutralizes SARS-CoV-2 and cross-reacts with VOCs, demonstrating its potential for nasal administration.
bioRxiv · Mar 17, 2023Biochemistry